Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1/2 3Phase EARLY_PHASE1 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × tafasitamab × Clear all
NCT05429268 2026-05-05

firmMIND

Incyte Corporation

Phase 3 Active not recruiting
82 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

Incyte Corporation

Phase 3 Active not recruiting
899 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡